Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Multiple Myeloma 202Leukemia, Lymphocytic, Chronic, B-Cell 54Recurrence 37Neoplasms, Plasma Cell 30Lymphoma, Mantle-Cell 30Lymphoma 30Lymphoma, Follicular 29Lymphoma, Large B-Cell, Diffuse 27Leukemia 23Leukemia, Myeloid, Acute 22Lymphoma, Non-Hodgkin 21Lymphoma, B-Cell, Marginal Zone 15Myelodysplastic Syndromes 13Hodgkin Disease 12Waldenstrom Macroglobulinemia 8Prostatic Neoplasms 8Lymphoma, T-Cell 8Smoldering Multiple Myeloma 7Immunoglobulin Light-chain Amyloidosis 7Neoplasms 6Melanoma 6Lymphoma, B-Cell 6Hematologic Diseases 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, T-Cell, Cutaneous 5Lymphoma, Large-Cell, Anaplastic 5Leukemia, Myelomonocytic, Chronic 5Hematologic Neoplasms 5Amyloidosis 5Sezary Syndrome 4

Interventions

Lovastatin 3Deoxycholic Acid 3AZD 6244 3pirfenidone 2Vinblastine 2Transcranial Direct Current Stimulation 2Sirolimus 2Polidocanol 2Lasers, Solid-State 2Inhalation 2Acetylcysteine 2tipifarnib 1pomalidomide 1peginterferon alfa-2b 1mirdametinib 1diphenylcyclopropenone 1binimetinib 1X-Rays 1Vincristine 1Temozolomide 1Surveys and Questionnaires 1Sunitinib 1Specimen Handling 1Sorafenib 1Saline Solution 1Ranibizumab 1Radiotherapy 1Photons 1Pharmacokinetics 1Neuropsychological Tests 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neurofibromatosis 1 × Lenalidomide × Clear all
NCT01553149 2025-01-07

Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma

National Cancer Institute (NCI)

Phase 2 Completed
75 enrolled 17 charts
CNS

Astrocytoma, Neurofibromatosis 1, Optic Nerve Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡